Abstract 179P
Background
HCC is the fourth most common malignancy in China, and ranks second by mortality rate. Most patients have already reached advanced stage when diagnosed. TACE in combination with first-lined systematic therapy has been explored as an effective treatment for unresectable HCC. However, it has not been reported the safety and efficacy of Regorafenib combined with TACE, as a second-lined therapy. In this multicenter retrospective study, we preliminarily investigated the safety and efficacy of a combination with Regorafenib and TACE therapy in patients with unresectable HCC.
Methods
We reviewed the medical data of 38 patients with progression after prior treatment of Sorafenib and/or Lenvatinib from Jan 2019 to Apr 2020 at 4 tertiary centers in China. Patients were treated with TACE initially after enrollment. 5-7 days after the first TACE, patients started taking Regorafenib PO for 3 weeks on/1 week off. All patients were required to be followed up regularly and TACE was repeated as needed. The overall survival (OS), time to progression (TTP), progression-free survival (PFS), drugs safety, adverse events (AEs) were observed. OS was calculated from date of first TACE to death. TTP was calculated from date of first TACE to progression. Adverse events were evaluated by Clavien classification. Drugs safety was investigated according to CTCAE v4.03.
Results
Baseline patient characteristics are presented in the table Table: 179P
Baseline patient characteristics
Baseline characteristic | Total (n=38) |
Age (years) | 59.4±9.19 |
Sex, n (%) | |
Male | 32 (84.2%) |
ECOG, n (%) | |
0 | 21 (55.3%) |
1 | 13 (34.2%) |
2 | 4 (10.5%) |
BCLC, n (%) | |
B | 18 (47.4%) |
C | 20 (52.6%) |
Hepatitis, n (%) | |
HBV | 32 (84.2%) |
HCV | 2 (5.3%) |
No | 4 (10.5%) |
Maximum tumor size (cm) | 3.75 (2.5, 7.5) |
Tumor number, n (%) | |
1 | 4 (10.5%) |
≥2 | 34 (89.5%) |
AFP (μg/L) | 50.85 (6.64, 1210) |
Extrahepatic metastasis, n (%) | 13 (34.2%) |
Portal vein invasion, n (%) | 12(31.6%) |
Prior Local Therapy, n (%) | |
Surgery | 13 (34.2%) |
Ablation | 20 (52.6%) |
TACE | 36 (94.7%) |
Radiotherapy | 6 (15.8%) |
Follow-up, months(range) | 5.6 (1.7,17.0) |
Prior Systemic Therapy, n(%) Sorafenib Lenvatinib Lenvatinib Sequential to Sorafenib | 33 (86.8%) 1(2.6%) 4(10.5%) |
Conclusions
Regardless of the retrospective nature, the present study as the first up-to-date real-world evidence indicates that Regorafenib combined with TACE was clinically effective and tolerable in subsequent to prior systemic therapy for unresectable HCC. Additional prospective large-scale studies are required to further verify our conclusion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session